Answers are grounded in this paper and cite their sources.
This review highlights thrombotic risks associated with immune thrombocytopenia and its treatments, indicating clinical considerations for management.
Patients with immune thrombocytopenia (ITP) have a higher thrombotic rate than the general population, and certain ITP treatments may further increase this risk. This narrative 'In a Nutshell' review provides an overview on thrombosis in adults with primary ITP and the haemostatic changes contributing to the hypercoagulability and thrombosis associated with ITP and its treatments.
No takes yet. Share an insight, caveat, or question.
Garabet et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: